Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV (Q87438713)
Jump to navigation
Jump to search
scientific article published on 01 November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV |
scientific article published on 01 November 2012 |
Statements
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer (English)
David R Spigel
Martin J Edelman
Kenneth O'Byrne
Luis Paz-Ares
Wei Yu
Karen Rittweger
Holger Thurm
MetLung Phase III Study Group